Al Sandrock (Biogen via YouTube)
Waving off recent PhII flop, Biogen trumpets early positive Alzheimer's data for anti-tau antisense
Even as Biogen execs scrambled to defend Aduhelm and paint a rosy future the drug promises to unleash, R&D chief Al Sandrock reassured analysts …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
